Observational Study of Elizaria® in aHUS Patients
Launched by AO GENERIUM · Feb 8, 2021
Trial Information
Current as of May 27, 2025
Completed
Keywords
ClinConnect Summary
After screening, patients meeting all of the inclusion / non-inclusion criteria and vaccinated against meningococcal infections were treated by Elizaria®.
The study is planned to include at least 50 patients receiving Elizaria® for the aHUS treatment.
The study will consist of a screening period of up to 4 weeks, including, if necessary, immunization with meningococcal vaccine, a treatment period of 52 weeks.
Medication will be prescribed in accordance with routine medical practice. Accordingly to minimize the risks and subjectivity of assessments the methods adopted in the routine pract...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria
- • 1. Written informed consent to study participation.
- • 2. Male and female patients aged 2 months and older with documented atypical hemolytic uremic syndrome (aHUS)diagnosis.
- • 3. By the time of inclusion in the study, Elizaria® should be prescribed as a pathogenetic therapy for aHUS; Exclusion Criteria
- • 1. Intolerance to eculizumab, or other components of the drug.
About Ao Generium
Ao Generium is a pioneering biopharmaceutical company dedicated to advancing innovative therapies for the treatment of rare and complex diseases. With a strong emphasis on cutting-edge research and development, Ao Generium leverages state-of-the-art technologies and a collaborative approach to accelerate the discovery and delivery of effective medical solutions. Committed to improving patient outcomes, the company actively engages in clinical trials that push the boundaries of current treatments and aim to address unmet medical needs. Through its dedication to scientific excellence and patient-centric initiatives, Ao Generium is poised to make a significant impact in the healthcare landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Kazan, , Russian Federation
Krasnoyarsk, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Moscow, , Russian Federation
Saint Petersburg, , Russian Federation
Saint Petersburg, , Russian Federation
Patients applied
Trial Officials
Oksana A. Markova, MD
Study Chair
AO GENERIUM
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials